Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia
暂无分享,去创建一个
B. Pégourié | S. Iacobelli | G. Gahrton | M. Mohty | A. Gratwohl | D. Niederwieser | R. Hájek | P. Moreau | H. Ludwig | N. Gorin | J. Harousseau | T. D. de Witte | T. Masszi | B. Hertenstein | C. Doyen | G. Milone | Curly T C M Morris | L. Garderet | I. Lafon | C. Chaleteix | C. Koenecke | A. Cakana | M. Michallet | F. Onida | P. Casassus | N. Ketterer | M. Dib | J. Fontan | B. Kolb | Marleen van Os
[1] D. Esseltine,et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.
[2] H. Goldschmidt,et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Baccarani,et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.
[4] M. Boccadoro,et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. , 2010, Blood.
[5] M. Boccadoro,et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Esseltine,et al. Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up , 2010 .
[7] J. Miguel,et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. , 2010, The Lancet. Oncology.
[8] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.
[9] P. Moreau,et al. Lenalidomide maintenance after transplantation for myeloma. , 2010 .
[10] K. Owzar,et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. , 2010 .
[11] P. Moreau,et al. Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study. , 2010 .
[12] A. Chanan-Khan,et al. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Boccadoro,et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Terol,et al. Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)â/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeâ as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial. , 2009 .
[15] K. Anderson,et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma , 2009, Leukemia.
[16] J. Reynolds,et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Dimopoulos,et al. Treatment of relapsed/refractory multiple myeloma. , 2009, Seminars in hematology.
[18] M. Dimopoulos,et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma , 2009, Leukemia.
[19] P. Moreau,et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma , 2008, Haematologica.
[20] A. Glasmacher,et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma , 2008, European journal of haematology.
[21] J. Crowley,et al. VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma , 2008, Leukemia.
[22] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[23] M. Gordon. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression , 2008 .
[24] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[25] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[26] J. Esteve,et al. Long‐term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration , 2006, European journal of haematology.
[27] Serge Leyvraz,et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.
[28] K. Anderson,et al. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma , 2006, Current opinion in oncology.
[29] John Crowley,et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.
[30] H. Goldschmidt,et al. A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma , 2006, British journal of haematology.
[31] A. Bosi,et al. Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients , 2006, Leukemia & lymphoma.
[32] M. Gordon. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .
[33] D. Esseltine,et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. , 2006, Haematologica.
[34] K. Sułek,et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma , 2004, British Journal of Cancer.
[35] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[36] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.